Topete-Camarena VM, Balandra-Ortiz JI, Ortega-González C, Reyes-Muñoz E

Language: Spanish
References: 26
Page: 88-93
PDF size: 154.06 Kb.

ABSTRACT

Introduction: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. It has been reported that women with PCOS have an increased risk of obstetric and perinatal complications. Objective: Know the obstetric and perinatal outcomes of Mexican women with history of infertility and PCOS. Material and methods: Cross sectional study, we included women with infertility and diagnosis of PCOS according to the Rotterdam criteria who achieved pregnancy, with unique product, prenatal care and the resolution in the National Institute of Perinatology in Mexico City, from January 2003 to April 2011. We excluded women with concomitant endocrinopathies. We analyzed the main maternal and fetal complications. Results: The frequency of maternal complications were gestational diabetes mellitus (GDM) 24.1%, abortion 15.5%, impaired glucose tolerance 13%, preterm delivery 10.7%, premature rupture of membranes 10.7% and pregnancy induced hypertension 9.6%. Conclusions: Mexican women with a history of infertility and PCOS have a higher frequency of GDM. The rest of obstetric and perinatal outcomes were similar to those reported in women without PCOS.

REFERENCES

1. Asunción M, Calvo R, San-Millán J, Sancho J, Ávila S, Escobar-Morreale H. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-38.

2. Azziz R, Woods K, Reyna R, Key T, Knochenhauer, Yildiz B. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-49.

3. Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest 2010; 69: 274-80.

4. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-36.

5. Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long term-health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7.

6. De Ugarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83: 1454-60.

7. Shamah-Levy T, Villalpando-Hernández S, Rivera-Dommarco J. Resultados de la Nutrición de la ENSENAUT 2006. Cuernavaca, México: Instituto Nacional de Salud Pública. 2007.

8. Heijnen EM, Eijkmans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12: 13-21.

9. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12: 673-83.

10. Instituto Nacional de Perinatología. Normas de procedimientos en obstetricia. Ed. Publicidad y Marketing de México. México 2003.

11. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33: S11-S61.

12. Jurado-García E, Abarca A, Osorio C, Campos R, Saavedra A, Álvarez J y cols. Evaluación del peso y la longitud corporal fetal en la Ciudad de México. Análisis estadístico de 16,807 nacimientos consecutivos de producto único vivo. Bol Méd Hosp Infant Mex 1970; 27: 163-95.

13. Mikola M, Hiilesmaa V, Haulttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001; 16: 226-29.

14. Ballagh SA, Harris HA, Demasio K. Is curettage hended for uncomplicated incomplete spontaneous abortion? Am J Obstet Gynecol 1998; 179: 1279-82.

15. Glueck C, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004; 10: 323-34.

16. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524-29.

17. Rai R, Backos M, Rushworth F, Regan L. Polycystic ovaries and recurrent miscarriage: a reappraisal. Hum Reprod 2000; 15: 612-15.

18. Tian L, Shen H, Lu Q, Norman RJ, Wang J. Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. J Clin Endocrinol Metab 2007; 92: 1430-33.

19. Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006; 55: 345-52.

20. Palomba S, Orio F, Falbo A, Russo T, Tolino A, Zullo F. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil Steril 2005; 84: 761-65.

21. Jakubowicz DJ, Essah PA, Sepp LM, Jakubowicz S, Baillargeon JP, Koistinen R et al. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 2004; 89: 833-39.

22. Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 2002; 54: 94-8.

23. Zhang J, Zeisler J, Hatch MC, Berkowitz G. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev 1997; 19: 218-32.

24. Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod 2003; 18: 1438-41.

25. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858-64.

26. Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol Metab 2002; 13: 364-68.